Indication (pathologie):
Paroxysmal nocturnal hemoglobinuria
Identifiant SNOMED-CT:
1963002
Etudes cliniques
-
A phase 3, randomized, parallel-group, multicenter, open-label, pharmacokinetic, noninferiority study of ravulizumab administered subcutaneously versus intravenously in adult patients with paroxysmal nocturnal hemoglobinuria currently treated with eculizumabPhase de l'étude: Phase IIIRecrutement: Ouvert
-
Randomized phase 3 study evaluating the efficacy and the safety of oral azacitidine (CC-486) compared to investigator’s choice therapy in patient with relapsed or refractory angioimmunoblastic T- cell lymphomaIndication (pathologie):T-cell lymphomaIdentifiant SNOMED-CT:109978004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenanceIndication (pathologie):T-cell lymphomaIdentifiant SNOMED-CT:109978004Phase de l'étude: Phase IIRecrutement: Ouvert
-
Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell LymphomaIndication (pathologie):Lymphome à cellules TIdentifiant SNOMED-CT:109978004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenanceIndication (pathologie):Lymphome à cellules TIdentifiant SNOMED-CT:109978004Phase de l'étude: Phase IIRecrutement: Ouvert
-
Role of micro-environment in acute leukemia: epigenetic regulationsIndication (pathologie):Leucémie aiguëIdentifiant SNOMED-CT:91855006Recrutement: Ouvert
-
A Multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patientsIndication (pathologie):MyelofibrosisIdentifiant SNOMED-CT:52967002Phase de l'étude: Phase IIRecrutement: Fermé
-
Prospective Registry of ICLUSIG® (ponatinib) used in clinical practice for the treatment of patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia in BelgiumIndication (pathologie):Leucémie myéloïde chronique (CML)Identifiant SNOMED-CT:92818009Indication (pathologie):Leucémie aiguë lymphoblastique (ALL)Identifiant SNOMED-CT:SCTID 91857003Recrutement: Ouvert
-
A phase II, international, multicenter, randomized, open-label, parallel group, randomized, study to evaluate the efficacy and safety of CC-486 (oral azacitidine) alone and in combination with durvalumab (MEDI4736) in subjects with myelodysplastic syndromes who fail to achieve an objective response to treatment with azacitidine for injection or decitabineIndication (pathologie):Syndrome myélodysplasiqueIdentifiant SNOMED-CT:109995007Phase de l'étude: Phase IIRecrutement: Fermé
-
A retrospective and prospective observational study of ibrutinib treatment of chronic lymphocytic leukemia and mantle-cell lymphoma in routine clinical practiceIndication (pathologie):Leucémie lymphoïde chronique (CLL)Identifiant SNOMED-CT:SCTID 92814006Indication (pathologie):Lymphome du manteauIdentifiant SNOMED-CT:443487006Phase de l'étude: Phase IVRecrutement: Ouvert
-
Sub-cutaneous rituximab-minichop versus sub-cutaneous rituximab-minichop + lenalidomide (R2-minichop) in diffuse Large B Cell lymphoma for patients of 80 years old or more. A multicentric phase III study of the Lymphoma Study Association (LYSA)Indication (pathologie):Lymphome diffus à grandes cellules (DLBCL)Identifiant SNOMED-CT:734076008Phase de l'étude: Phase IIIRecrutement: Fermé
-
National registry to evaluate real-life use of ADCETRIS® (brentuximab vedotin) in BelgiumIndication (pathologie):Lymphome de HodgkinIdentifiant SNOMED-CT:118599009Recrutement: Fermé
-
A multicenter, open-label, single-arm, Phase IIIB, international study evaluating the safety of obinutuzzumab alone or in combination with chemotherapy in patients with previously untreated or relapsed/refractory chronic lymphocytic leukemiaIndication (pathologie):Leucémie Lymphoide ChroniqueIdentifiant SNOMED-CT:92814006Phase de l'étude: Phase IIIRecrutement: Fermé
-
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated T-cell lymphomaIndication (pathologie):Lymphome à cellules TIdentifiant SNOMED-CT:109978004Phase de l'étude: Phase IIIRecrutement: Fermé
-
A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive chronic myeloid leukemia after two different durations of consolidation treatment with nolitinib 300mg BIDIndication (pathologie):Leucémie myéloide chroniqueIdentifiant SNOMED-CT:92818009Phase de l'étude: Phase IIIRecrutement: Fermé
-
A randomized phase III study using a pet-driven strategy and comparing GA101 versus rituximab in combination with a chemotherapy delivered every 14 days (ACVBP or CHOP) in DLBCL CD20+ lymphoma untreated patients from 18 to 60 years presenting with 1 or more adverse prognostic factors of the age-adjusted IPIIndication (pathologie):Lymphome diffus à grandes cellules (DLBCL)Identifiant SNOMED-CT:734076008Phase de l'étude: Phase IIIRecrutement: Fermé
-
A phase III open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphomaIndication (pathologie):Lymphome folliculaireIdentifiant SNOMED-CT:109971005Phase de l'étude: Phase IIIRecrutement: Fermé
-
Randomized phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk(aa IPI=0) diffuse large B-cells non Hodgkin's lymphoma CD20+Indication (pathologie):Lymphome diffus à grandes cellules (DLBCL)Identifiant SNOMED-CT:734076008Phase de l'étude: Phase IIIRecrutement: Fermé
-
Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor stage III-IV or high risk IIB Hodgkin lymphomaIndication (pathologie):Lymphome de HodgkinIdentifiant SNOMED-CT:118599009Phase de l'étude: Phase IIIRecrutement: Fermé
-
10-day decitabine versus conventional chemotherapy "3+7" followed by allografting in acute myeloid leukemia in patients ≥ 60 years: A randomized phase-III study of the EORTC leukemia group, CELG, GIMEMA and German MDS study groupIndication (pathologie):Leucémie myéloide aiguëIdentifiant SNOMED-CT:91861009Phase de l'étude: Phase IIIRecrutement: Fermé